29.6.2017 14:01 | Nasdaq OMX
Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury
InSphero AG / Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Archives of Toxicology publication reveals microtissues are twice as sensitive as 2D primary human hepatocytes (PHH) for predicting hepatotoxicity of 110 clinically defined DILI compounds.
Schlieren, Switzerland, June 29, 2017 (GLOBE NEWSWIRE) -- In the most comprehensive evaluation of 3D spheroid hepatic cultures conducted to date, a publication co-authored by lead toxicologists and drug safety experts at AstraZeneca and Genentech revealed InSphero 3D InSight(TM) Human Liver Microtissues to be a more sensitive and highly specific in vitro model for predicting drug-induced liver injury (DILI) compared to 2D models. The study entitled, "Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury ," was published online Tuesday, June 13 in the journal Archives of Toxicology . Dr. William Proctor, Head of Investigative Toxicology at Genentech, and Alison Foster, Senior Scientist in the Drug Safety and Metabolism group at AstraZeneca, were co-first authors on the publication.
2D PHH assays have been the "gold-standard" model used for DILI testing, yet DILI still remains one of the leading sources for drug attrition, black box warnings, and post-market withdrawal of drugs. Thus, there is a growing need for better predictive tools to assess liver injury earlier in the drug development process. The authors note in the paper that, "3D models have shown promise in small sets of DILI compounds, but a more comprehensive retrospective study of DILI positive and negative drugs to test the predictive power of 3D models head to head with 2D PHH assays had not been performed."
The study determined that regardless of the threshold used, "Human Liver Microtissues demonstrated increased sensitivity in identifying known hepatotoxicants versus PHH, while specificity was consistent across both assays." Microtissues also, "outperformed PHH in correctly classifying hepatotoxicants from different pharmacological classes of molecules." Furthermore, the authors found that 3D microtissues displayed sufficient structural and functional characteristics to warrant exploratory studies to see if novel biomarkers used in the clinic could also be detected in vitro . Findings revealed that despite each microtissue consisting of ~1000 cells, the mechanistic and exploratory hepatotoxicity biomarkers miR-122, HMGB1, and alpha-GST could be detected in the culture supernatants, demonstrating that, "3D liver microtissues have the potential to recapitulate in vivo findings in vitro ."
"This landmark study provides convincing, independent evidence that InSphero liver microtissues can help identify hepatotoxic drugs with greater sensitivity without sacrificing specificity, says InSphero Chief Executive Officer and Co-founder Dr. Jan Lichtenberg. "Having two of the world's leading pharmaceutical companies collaborate to produce this thorough validation further confirms that our 3D models not only better reflect in vivo biology, but also deliver the reproducibility and scalability required to meet the early stage screening demands of large pharma. Our assay-ready 3D InSight(TM) models offer a cost-effective, turnkey solution that gives toxicologists greater confidence when characterizing risk in lead compound sets."
3D InSight(TM) Human Liver Microtissues are a standardized primary human liver model developed by InSphero that display enhanced liver phenotype, metabolic activity, and stability over 28 days in culture, enabling long-term drug exposure studies not attainable with 2D hepatic models.
For more information about InSphero 3D InSight(TM) Liver Microtissues and applications, visit www.insphero.com
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight(TM) Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.
InSphero 3D InSight(TM) solutions drive significant findings in peer-reviewed journals , through collaborative industry initiatives such as EU-ToxRisk and HeCaToS , and have gained validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies.
Founded in 2009, the privately held company is headquartered in Switzerland, with subsidiaries in the United States and Germany. It has been recognized for its scientific and commercial achievements with several national and international awards .
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/49b63be5-b99c-4789-82ec-255febd1bef4
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/cd947eeb-93b5-4005-9072-76223d78942a
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6f21ed8c-d6f6-4bd2-bf0e-f6e0e46ea6ff
+41 44 515 0490
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
RedHill Biopharma Ltd.25.7.2017 13:23 | pressemeddelelse
RedHill Biopharma Reports 2017 Second Quarter Financial Results
Compuware Corporation25.7.2017 12:01 | pressemeddelelse
Compuware and Wipro Jointly Launch a Mainframe Center of Excellence
VITEC25.7.2017 10:32 | pressemeddelelse
VITEC to Showcase Field-Proven Military and Defense Video Streaming Solutions at DSEI
Nasdaq25.7.2017 09:01 | pressemeddelelse
Nasdaq to Acquire Sybenetix
Novavax, Inc.24.7.2017 22:07 | pressemeddelelse
Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs
LedgerX24.7.2017 21:53 | pressemeddelelse
Announcing the First U.S. Federally Regulated Exchange and Clearing House for Digital Currency Derivatives
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum